Overactive Bladder News and Research

RSS

Overactive bladder (OAB) is a urological condition defined by a set of symptoms: "urgency, with or without urge incontinence, usually with frequency and nocturia."

AUA updates clinical practice guideline on female stress urinary incontinence

A complete evaluation, including an assessment of post-void residual volume, is key when evaluating a female patient for surgery to treat stress urinary incontinence (SUI), according to a new clinical practice guideline released today by the American Urological Association (AUA).

8 Jan 2010

Urigen Pharmaceuticals and Oceana Therapeutics jointly prepare for meeting with FDA on URG101

Urigen Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that the Company and Oceana Therapeutics have agreed to jointly prepare for a meeting with the U.S. Food & Drug Administration regarding the continued development of URG101.

22 Dec 2009

Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced top-line efficacy and safety results for the phase IIb clinical trial for XIAFLEX™ (collagenase clostridium histolyticum) in the treatment of Peyronie's disease.

16 Dec 2009

Uroplasty to publish 12-month results of its OrBIT Urgent PC Neuromodulation System trial

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted the 12-month results of the OrBIT Trial of its Urgent® PC Neuromodulation System that will be published in the January 2010 print edition of THE JOURNAL OF UROLOGY®.

10 Dec 2009

TARIS Biomedical completes Phase 1 study of its intravesical drug-device convergence system

TARIS Biomedical, a specialty pharmaceutical company pioneering the field of drug-device convergence for targeted therapies, announced today the successful completion of a Phase 1 clinical study of its intravesical drug-device convergence system designed to provide sustained-release of drug directly to the bladder.

2 Dec 2009

Most Canadians hope OAB symptoms will go away

A recent poll conducted by Leger Marketing, on behalf of the Powder Room - a national education program for those with overactive bladder (OAB) - asked 1,500 Canadians about their bladder health. The findings revealed that although people are experiencing OAB symptoms, most are choosing not to seek medical attention - perhaps assuming the frustrating and embarrassing symptoms will go away, or that they will just have to live with them.

23 Nov 2009

Data from second positive pivotal study of PSD502 for treatment of PE presented

At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora")., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).

20 Nov 2009

Positive results from Sciele Pharma's second pivotal study of PSD502 for the treatment of PE

At the annual meeting of the Sexual Medicine Society of North America, Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC, today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).

19 Nov 2009

Presentations to highlight durability and efficacy of urethral bulking agents

Uroplasty, Inc. (AMEX: UPI), a medical device company developing, manufacturing and marketing innovative proprietary products for the treatment of voiding dysfunctions, today announced that nine abstracts outlining study results submitted by various researchers have been accepted for presentation at the 2010 Annual Meeting of the Society for Urodynamics and Female Urology (SUFU), February 23-27, 2010 in St. Petersburg, FL. Presentations accepted were for both Uroplasty's Urgent® PC Neuromodulation System and Macroplastique® urethral bulking agent products.

17 Nov 2009

Medtronic launches an educational campaign to raise awareness of overactive bladder

Medtronic, Inc. today announced the kick-off of an educational campaign aimed at raising awareness among women of overactive bladder (OAB), a serious condition that can severely impact patients’ lives. This new campaign, conducted in partnership with leading patient advocacy groups focused on women’s health will help to raise awareness of the prevalence of bladder control problems and encourage patients to find effective treatment options – including and beyond medications.

13 Nov 2009

Warner Chilcott reports a net income of $424.2M for the quarter ended September 30, 2009

Warner Chilcott plc today announced its results for the quarter ended September 30, 2009. Revenue in the quarter ended September 30, 2009 increased 9.0% to $252.8 million over the prior year quarter. The primary drivers of the increase in revenue in the quarter were the net sales of LOESTRIN 24 FE and ESTRACE Cream which were partially offset by net sales declines of other products, primarily TACLONEX.

9 Nov 2009

Allergan reports operating results for the third quarter of 2009

Allergan, Inc. today announced operating results for the quarter ended September 30, 2009. Allergan also announced that its Board of Directors has declared a third quarter dividend of $0.05 per share, payable on November 30, 2009 to stockholders of record on November 9, 2009.

29 Oct 2009

Auxilium Pharmaceuticals reports increased net revenues of $42.1 million in third quarter 2009

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced financial results and operational highlights for the quarter ended September 30, 2009. For the third quarter of 2009, Auxilium reported net revenues of $42.1 million compared to net revenues of $32.6 million in the third quarter of 2008.

28 Oct 2009

Urigen Pharmaceuticals announces a presentation on interstitial cystitis/painful bladder syndrome

Urigen Pharmaceuticals, Inc., focused on the development of treatments for urologic disorders and pain, announces a presentation at its offices on October 30, 2009 at 2PM PST. The slides presented will be posted to its website at www.urigen.com after the close of trading that day.

28 Oct 2009

Study explores the link between LUTS and depression, anxiety disorders, sexual trauma

Depression, anxiety disorders and sexual trauma have all been implicated as risk factors in lower urinary tract symptoms (LUTS) such as incontinence and overactive bladder.

20 Oct 2009

Update from Endo Pharmaceuticals regarding its New Drug Application for FORTESTA

Endo Pharmaceuticals today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for FORTESTA(TM) (testosterone) 2% Gel for men diagnosed with low testosterone (Low T), also known as hypogonadism.

19 Oct 2009

Uroplasty's Urgent PC and Macroplastique presented at the International Continence Society Meeting

Uroplasty, Inc., a medical device company developing, manufacturing and marketing innovative proprietary products for the treatment of voiding dysfunctions, today highlighted presentations, workshops and posters focused on its products at the 39th Annual Meeting of the International Continence Society Meeting (ICS), September 29 - October 3 in San Francisco.

7 Oct 2009

Fifth SEEM anniversary meeting to be held in Belgrade

On 9 and 10 October the anniversary South Eastern European Meeting (SEEM) will be held in the Yugoslav Drama Theatre (Jugoslovensko Dramsko Pozoriste) in Belgrade (RS). Professor Michael Marberger (Vienna, AT), chairman of the Regional Office of the European Association of Urology: "For the 5th time the SEEM will provide a platform where new experimental and clinical work from the region is presented to an international audience".

5 Oct 2009

Auxilium Pharmaceuticals raises $115.7 million for general corporate purposes

Auxilium Pharmaceuticals, Inc. announced today that it has closed its previously announced public offering of 3,000,000 shares of its common stock at a price of $34.50 per share.

3 Oct 2009

Quintiles Transnational enter into marketing agreement with Allergan for SANCTURA XR

Quintiles Transnational Corp. and Allergan, Inc. (NYSE: AGN) today announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR® (trospium chloride extended release capsules), an anticholinergic approved for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency, predominantly to primary care physicians in the United States.

28 Sep 2009